back home
30-11-2022 Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 23-11-2022 Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting 11-12-2020 Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST® 09-12-2020 Sanofi and Kiadis satisfy competition condition related to the tender offer 21-01-2020 Pharming receives EMA approval of new facility for expansion of RUCONEST® production 14-01-2020 Pharming announces the placement of €125 million senior unsecured convertible bonds due 2025 14-01-2020 Pharming announces the launch of an offering of approximately €125 million senior unsecured convertible bonds due 2025 07-01-2020 Polyganics Achieves CE Mark Certification for LIQOSEAL® 25-02-2019 Pharming announces abstract presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAI Lectureship 31-10-2017 BioGeneration Ventures Fund III reaches EUR 82 million in final close 23-10-2017 Pharming announces warrant exercises and conversions of its Ordinary Bonds into shares mostly through cashless exercise 18-10-2017 BioGeneration Venture’s portfolio company SurgVision acquired by Bracco Imaging 03-10-2017 Dutch Mellon Medical secures € 6 million for market introduction of major innovation in surgical suture technology: single-handed suturing using the Switch® 02-10-2017 Pharming announces positive data from paediatric clinical trial with RUCONEST® 26-09-2017 Pharming Group N.V. and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for “HAEi Global Access Program” 26-07-2017 Pharming announces publication of RUCONEST® prophylactic data in The Lancet 21-07-2017 Pharming announces completion of its refinancing with a single US$100 million debt facility on improved commercial terms 12-07-2017 Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data 06-07-2017 Agendia's MammaPrint® recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update 03-04-2017 ENG EUR 12,8 miljoen nieuwe financiering voor biotechonderneming Cristal Therapeutics eng 14-03-2017 BioGeneration Ventures contributes to Cristal Therapeutics EUR 12.8 million Financing Round 13-02-2017 Europese Commissie breidt marketingvergunning RUCONEST® uit met zelfstandige toediening 08-12-2016 Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant 07-12-2016 Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform 07-12-2016 Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform


Bekijk hier de online versie



  • Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates
  • Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates

​Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other diseases and iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, using Cristal Therapeutics’ medicinal nanotechnology CriPec® platform.

The initial goal of this partnership is to determine the therapeutic efficacy of targeted drugs using Cristal’s CriPec® application in iTeos’ preclinical models which have been proven to be predictive in combinations of several immune activators - such as IDO1 and TDO2 - with checkpoint inhibitors. iTeos has an option to license Cristal’s proprietary nanotechnology platform to support the development and commercialization of up to three of its immune tumor-targeting programs.

CriPec®, a proprietary nanotechnology platform, consists of tuneable polymers and biodegradable drug linkers that allow for the rational design and straightforward manufacturing of custom-made nanomedicines. Applying the CriPec® platform - drugs entrapped in CriPec® nanoparticles - results in immuno nanomedicines with a superior product profile as compared to the native drug molecule. CriPec® nanoparticles improve the disposition of thousands of drug molecules per particle and allow the controlled release of these molecules specifically at the target site. This results in an improved therapeutic efficacy and tolerability.

Joost Holthuis, Cristal Therapeutics’ CEO, commented: 

“This partnership with iTeos allows us to assess and demonstrate the application of our CriPec® nanoparticles, specifically in the area of novel immuno-oncology therapies. We are focused on applying our nanomedicine platform to several promising oncology indications, some of which will be evaluated for the iTeos’ development pipeline.” 

Michel Detheux, iTeos’ CEO, added: 

“We are very pleased to enter into this partnership with an emerging clinical-stage nanomedicine platform company. Cristal has a strong and experienced management team, and has demonstrated the capability to quickly develop valuable therapeutic programs. We look forward to applying their platform to some of our drug candidates. We believe it has particular potential in the evolving area of causing so-called “cold tumors” – which are less responsive to checkpoint inhibitors - to become susceptible to various immuno-oncology therapies.”

About Cristal Therapeutics

Maastricht, The Netherlands based Cristal Therapeutics, is a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform. CriPec® transforms drugs into polymeric nanoparticles via an innovative process. These nanoparticles provide improved distribution throughout the body. The substantial improvement of the efficacy and safety of the drugs entrapped in CriPec® nanoparticles has been demonstrated in several preclinical disease models. Cristal Therapeutics’ products in development are primarily aimed at treating patients suffering from cancer but offer also opportunities for the treatment of chronic inflammatory diseases. CriPec® docetaxel is the most advanced product candidate, and is under clinical evaluation for the treatment of solid tumors. For more information please visit www.cristaltherapeutics.com.

About iTeos Therapeutics S.A.

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors.  It  has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com





Joost Holthuis, CEO

Cristal Therapeutics

+ 31 43 388 5868



Michel Detheux, CEO

iTeos therapeutics

+32 71 919 933



For iTeos Therapeutics:

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362-1200



Jonathan Birt, Mathew Neal, Hendrik Thys

Consilium Strategic Communications


+44 2 037 095 700


For Cristal Therapeutics:

LifeSpring Life Sciences Communication

Leon Melens


+31 6 538 16 427


Copyright © 2016 LifeSpring LifeSciences Communication, All rights reserved. 


Our address is: 
LifeSpring LifeSciences Communication
Science Park 400
1098 XH Amsterdam



Science Park 400 Matrix II Building 1098 XH Amsterdam +31 (0)653816427

  • - Corporate Communications
  • - Healthcare PR
  • - Financial Communications
  • - Content Marketing
  • - Social Media and Online Communications